



The First Contract Manufacturing Line for **CGM FLY** in China



2025
There are as many as
589,000,000
diabetic patients
worldwide

CGM market: Growing demand for continuous glucose monitoring ◀



The global **CGM** (Continuous Glucose Monitoring) market is witnessing steady growth. The key growth drivers are:



Growing number of people with diabetes: more than **589 million** according to IDF (International Diabetes Federation)


- Shift in demand from invasive control methods (test strips, glucose meters) to more convenient and accurate **CGM** systems
- Integrations with digital technologies and health management apps



The global **CGM** market is expected to exceed \$ **20 billion** by **2030**.

CGM systems market growth dynamics in the UAE

UAE market dynamics forecast




The number of CGM units consumed per year will increase 102 times




During the forecast period, the **UAE** market is expected to grow at one of the highest annual growth rates of **25%**. Sales of **CGM** systems will grow **102** times by **2045** from USD **35** million to USD **3,587.1** million.

The market research was commissioned by the **MLC** project as part of its analysis of the market for **CGM** devices.

CGM systems market growth dynamics in the Middle East and Africa



Middle East and Africa market dynamics forecast




Le nombre d'unités **CGM** utilisées par an augmentera de **69** fois

According to **MegaResearch** analysts, by **2045** the **Middle East and Africa CGM** market will show the highest growth rate of all regional markets amounting to **22%** per year. Thus, by **2045**, the market will increase **69** times in volume and **62** times in value.

The market research was commissioned by the **MLC** project as part of its analysis of the market for **CGM** devices.


CGM systems market growth dynamics in Vietnam

Vietnam market dynamics forecast




The CGM market in Vietnam is expected to grow 20 times over the forecast period

CGM systems market growth dynamics in South Asia and Oceania



South Asia and Oceania market dynamics forecast



The number of **CGM** units consumed per year will increase **22** times




According to **MegaResearch** analysts, by **2045** the market of **CGM** systems in **South Asia and Oceania** will grow **22** times in volume and value terms. The annual growth rate will amount to **15-16%**


India accounts for the largest regional market share

During the forecast period, consumption in India is expected to increase by **17.2%** annually to grow **5.8** times over the next **10** years

CGM systems market growth dynamics in Western Europe



Western Europe market dynamics forecast



The number of **CGM** units consumed per year will increase **35** times


The top 3 consumers represented by Germany, Spain, and France account for 51% of the Western Europe CGM market.




According to **MegaResearch** analysts, the **Western Europe CGM** market is estimated to increase by **18%** annually to grow **35** times in volume and **26** times in value terms by **2045**.

The market research was commissioned by the **MLC** project as part of its analysis of the market for **CGM** devices.

CGM systems market growth dynamics in Latin America



Latin America market dynamics forecast



The number of **CGM** units consumed per year will increase **4.4** times.

Brazil is the largest regional market with a 39% share.
Consumption of these systems will continue to grow increasing by 90% in 10 years.



MegaResearch analysts estimate that the **Latin America CGM** systems market will grow by **7%** annually to increase **4.4** times in volume terms and **9.4** times in value terms by **2045**.

Market opportunities and market development trends ◀

1. In 2024, the market for continuous glucose monitoring systems was estimated at 98.6 million devices, representing a value of USD 10,953 million.
2. At the current sales level, the supply of patients diagnosed with diabetes is about 0.5% of the total number of diabetics in the world.
3. CGM systems are the next generation of glucose monitoring technology. Traditional finger prick technology will be gradually replaced by CGM technology. At the same time, both technologies will continue to be present in the market, complementing each other.
4. The major driver of demand for these devices is the increasing incidence of diabetes across the globe, as well as the high technological effectiveness, painlessness, and ease of use that these devices offer.
5. The market has high growth potential. The potential market size, assuming 100% supply of devices to all diabetic patients, is 16.7 billion units. Thus, the current actual market (sales volume) of CGM systems is 0.5% of the potential consumption volume.
6. The market for continuous glucose monitoring systems is expected to experience an accelerated growth rate by 2045. Experts forecast a compound annual growth rate of 15%.
7. Under favorable conditions, the market will grow from 98.6 million to 2,343.4 million devices per year (23.8 times) by 2045, equivalent to a growth from 10,953.3 million to 233,127.7 million USD (21.3 times).
8. Provision of devices will amount to 11.5% of the total number of diabetic patients.

► Limitations of traditional diabetes control methods



Fragmentary nature of data: Glucose meters only provide point measurements of sugar levels, making it impossible to see the full picture.



Low monitoring frequency: Few patients adhere to the recommended frequency of measurements, thus reducing therapy efficacy.



Human factors: Dependence on manual control, forgetting about measurements and discomfort associated with finger pricking all lead to inaccuracies and risks.



Limited forecasting: Traditional methods cannot proactively detect trends and prevent acute conditions such as hypoglycemia.







► MLC International Community



WE ARE SUPPORTED BY

Over **80 000** participants
from **174** countries





Intellectual property valuation commissioned by the **MLC project** has been carried out by an independent company ◀

MLC holds key rights to the continuous glucose monitoring technology (**CGM Fly**), which include:



PATENTED TECHNOLOGY



A series of patents on the applied technology for the **CGM** system



International patent applications have been filed in **59** more countries

COMMERCIAL VALUE



According to independent experts, the cost of the project's intellectual property is estimated at \$ **108 million**



Scale-up potential through licensing and strategic partnerships

COMPETITIVE BARRIERS





Patented solutions prevent direct copying of the technology



Intellectual property is the cornerstone of capitalization and long-term sustainability of **MLC's** business

► Legal framework





Number of days, days




Invest in real high-tech production and earn a profit from real economic activities.

ADVANTAGES OF INVESTING




Transparent
business model



Regular income
from economic
activities



Stable market
demand



Control and participation
in developing the project

► What does an investor get?



Up to **50%**
of investment shares are held
by investors: participation in a
real, physically scalable
business with proven market
demand.
**SHARE IN THE FIRST CONTRACT
MANUFACTURING LINE.**



ATTRACTIVE ENTRY POINT
discount on early-stage shares,
with the capitalization
opportunity upon launching and
scaling up.

Up to **50%**
of income received based on
financial performance.
DIVIDEND YIELD POTENTIAL



ASSET VALUE GROWTH
growth in the investment value
of shares as serial production is
reached and agreements are
entered into.



Planned financial performance of organizing the production of **CGM** systems in the **MLC** project estimated by **MegaResearch** marketing company


A 6-year planning period was adopted in the economic evaluation of the project.

Production plan for continuous glucose monitoring (CGM) systems

Indicator	Unit of measurement	2025	2026	2027	2028	2029	2030
Continuous glucose monitoring (CGM) system	Pcs	Pilot batch 10,000	1,000,000	10,000,000	20,000,000	30,000,000	40,000,000

The calculation of net discounted income (**Net Present Value**, commonly used abbreviation is **NPV**) is a standard method for assessing the effectiveness of an investment project, which shows a high estimate of the investment effect, aligned to the present moment taking into account the different time value of money.

Dynamics of change in **NPV** of the project, \$ thousand



EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the profit made by a business before covering the income tax, interest on loans and depreciation.

This indicator reflects the overall performance of the enterprise and its ability to meet its obligations.

Item of income (expenditure)/year	2025	2026	2027	2028	2029	2030
EBITDA		18 071	276 687	585 683	926 279	1 298 433

The performed calculation shows that the project will become profitable starting from year two of its implementation.

The Profitability Index (PI) of the project is **6,762.45** units.

Internal rate of return (**IRR**) of the project is **546.3%**.

Calculated return on sales in the accruing period :

Item of income (expenditure)/year	2025	2026	2027	2028	2029	2030
Return on sales	0%	30%	45%	47%	48%	50%

In **2025**
pilot batch
10,000 units

In **2026**
sales
1,000,000 units





To be determined after the production line is formed and launched, and the planned production volume is reached.

**INVEST IN REAL
PRODUCTION!**